Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Short Interest Update

Posted by Geri Gentry on Aug 29th, 2026

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 3,812 shares, a decline of 49.6% from the July 30th total of 7,564 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 150,205 shares, the short-interest ratio is currently 0.0 days.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.6%

Shares of SGIOY stock opened at $9.04 on Friday. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $7.65 and a one year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock has a fifty day moving average price of $8.85 and a 200 day moving average price of $9.76. The stock has a market cap of $15.39 billion, a P/E ratio of 9.04, a price-to-earnings-growth ratio of 3.36 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Shionogi & Co., Ltd. Unsponsored ADR stock. Birmingham Capital Management Co. Inc. AL purchased a new position in shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,950 shares of the company’s stock, valued at approximately $257,000. Hedge funds and other institutional investors own 1.92% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on SGIOY. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy”.

Get Our Latest Research Report on Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

(Get Free Report)

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.